Metastatic colorectal cancer: therapeutic options for treating refractory disease.

Metastatic colorectal cancer: therapeutic options for treating refractory disease. Curr Oncol. 2019 Nov;26(Suppl 1):S24-S32 Authors: Parmar A, Chan KKW, Ko YJ Abstract Therapeutic options for chemorefractory metastatic colorectal cancer (mcrc) have significantly expanded since 2009. The oral targeted therapies regorafenib and trifluridine/tipiracil have been established to be efficacious and safe in patients with mcrc who have progressed beyond 2 or more lines of chemotherapy. Evidence for the use of immunotherapy in a subgroup of this patient population is also encouraging, particularly in patients with mcrc that exhibits high microsatellite instability or deficient mismatch repair. Those significant advances have led to Health Canada approval of 3 novel therapeutic options for the treatment of patients with chemorefractory mcrc. However, the limited clinical efficacy of those treatments underscores the need for ongoing development of systemic therapy options for this unique cohort of patients. Here, we review the current and emerging treatment landscape for chemorefractory mcrc. PMID: 31819707 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Related Links:

Authors: Lee YS, Cho YB Abstract The tumor microenvironment is the primary location in which tumor cells and the host immune system interact. There are many physiological, biochemical, cellular mechanisms in the neighbor of tumor which is composed of various cell types. Interactions of chemokines and chemokine receptors can recruit immune cell subsets into the tumor microenvironment. These interactions can modulate tumor progression and metastasis. In this chapter, we will focus on chemokine (C-C motif) ligand 7 (CCL7) that is highly expressed in the tumor microenvironment of various cancers, including colorectal c...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Abstract To achieve an enhanced anticancer effect of drug to treat colorectal cancer, a dual-targeted (i.e., ligand-tailored and pH-triggered) multiparticulate system has been designed to deliver drug directly into the colon domain. In this regard, folic acid-grafted solid lipid nanoparticles (SLNs) bearing irinotecan were encapsulated in microbeads of alginates. Afterward, these microbeads were coated with enteric polymer (i.e., Eudragit S100) to make them pH-responsive. COLO-205 cells were used to determine in vitro cytotoxicity potential of various formulations. Findings for IHT loaded FA-coupled SLNs suggested...
Source: International Journal of Biological Macromolecules - Category: Biochemistry Authors: Tags: Int J Biol Macromol Source Type: research
Results from this study recently published online in Addiction found primary care physicians providing smokers with a free, two week starter kit of nicotine replacement therapy (NRT) increased quit attempts While sitting in the dentist's office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea. As he received his goody bag with dental hygiene products, he wondered why not conduct a study and have primary care providers do the same thing for their patients who use tobacco. The bags would contain educational material, free lozenges and tobacco cessati...
Source: Dental Technology Blog - Category: Dentistry Source Type: news
In this study, we aimed to develop and characterize an optimal self-microemulsifying delivery system (SMEDS) formulated for 5-DTAN and to assess its anticancer activity in a xenograft model. SMEDS is a lipid-based formulation and typically comprises oil, surfactant, and co-surfactant. The results from our solubility and compatibility test revealed that ethyl oleate and d-limonene were appropriate for use as an oil phases. The optimal formulation comprised ethyl oleate / d-limonene (10% / 5%), Cremophor® EL (59.5%), and PEG 400 (25.5%). With this optimal formulation, the mean particle size was 97.1 ± 6.50 nm with...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conditions:   Colorectal Cancer Stage II;   Colorectal Cancer Stage III Interventions:   Drug: Metronidazole Oral Tablet;   Drug: Placebo oral tablet Sponsors:   Shanghai Jiao Tong University School of Medicine;   Shanghai Municipal Commission of Health and Family Planning Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study was conducted following theCochrane Handbook for Systematic Reviews of Interventions and the PRISMA guidelines. A systematic screening of the electronic databases was performed (Medline, Web of Science and Scopus). The validity of the pooled results was verified through the performance of trial sequential analysis (TSA). The level of evidence was estimated using the GRADE approach.ResultsOverall, 21 studies and 2498 patients were included in our study. Pooled comparisons and TSA analyses reported a superiority of LC over OC in terms of postoperative complications (OR 0.64,p = 0.0003), blood loss (W...
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
FRIDAY, Feb. 7, 2020 -- Lower-gastrointestinal (GI) bleeding is associated with high risks for colorectal cancer in patients with atrial fibrillation treated with oral anticoagulation (OAC) therapy, according to a study published online Feb. 6 in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionOral bisphosphonate use did not appear to be associated with elevated or reduced risk for GI cancers.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
CONCLUSIONS Downregulation of CCAT1 suppressed TCA-8113 cell proliferation, invasion, and migration by inactivation of the ERK/AKT pathway via inhibition of DDR2, suggesting the value of CCAT1 in diagnosis and treatment of patients with OSCC. PMID: 32009633 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Pappa Chlichlia The role of dietary probiotic strains on host anticancer immune responses against experimental colon carcinoma was investigated. We have previously shown that Lactobacillus casei administration led to tumor growth suppression in an experimental colon cancer model. Here, we investigated the underlying immune mechanisms involved in this tumorgrowth inhibitory effect. BALB/c mice received daily live lactobacilli per os prior to the establishment of a syngeneic subcutaneous CT26 tumor. Tumor volume, cytokine production, T cell differentiation and migration, as well as tumor cell apoptosis were examined t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Gastroschisis Repair | Immunotherapy | Oral Cancer